AML-391 Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients With Acute Leukemia With and Without Mixed-Lineage Leukemia (MLL)– Rearrangement or Nucleophosmin 1 (NPM1) Mutation

Naval Daver, John Affinito, Hongliang Cai, Hanna Dobrowolska, Ken Eguchi, Jay Stoudemire, Akinobu Watanabe, Matthew Hitron

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'AML-391 Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients With Acute Leukemia With and Without Mixed-Lineage Leukemia (MLL)– Rearrangement or Nucleophosmin 1 (NPM1) Mutation'. Together they form a unique fingerprint.

Medicine & Life Sciences